Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
UK pharma major AstraZeneca today announced extended indication approvals of two major products in Japan. 24 August 2023
Biotechnology
Japanese mid-size drugmaker Kyowa Kirin says it has received approval from the Ministry of Health, Labor and Welfare (MHLW) for partial change of approved indication of Lumicef (brodalumab [genetical recombination]) for the treatment of palmoplantar pustulosis (PPP) that respond inadequately to existing therapies. 24 August 2023
Biotechnology
US mRNA specialist Moderna saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine. 22 August 2023
Biotechnology
Chinese biopharma Hutchmed has announced that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate in adults with primary immune thrombocytopenia (ITP) in China. 21 August 2023
Pharmaceutical
Daewoong Pharmaceutical has already won approvals for its indigenous therapies—sodium–glucose linked transporter-2 (SGLT-2) inhibitor Envlo (enavogliflozin) and its metformin combination drug Envlomet—in South Korea. 18 August 2023
Pharmaceutical
Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF, UK Pharma major AstraZeneca announced this morning. 18 August 2023
Biotechnology
Singapore-listed healthcare company Medi Lifestyle has announced a collaboration involving its subsidiaries, HealthPro Pharma and Healthpro Marketing, with FIOR Bioscience and Shine Bioscience. 16 August 2023
Pharmaceutical
According to the official website of the China State Drug Administration the application for marketing authorization of Feisumei (benaglutide) injection for obesity or overweight indications declared by Benemae Pharmaceuticals/Renhui Biotech was approved for weight management of adults. 16 August 2023
Pharmaceutical
US CNS specialist Corium and Taiwan-based Lotus Pharmaceutical have entered into an exclusive collaboration and license deal for Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in 10 markets across Asia. 11 August 2023
Biotechnology
Following the approval of toripalimab, the drug is expected to get a first-mover advantage in the first-line treatment setting within the PD-1 market in RCC for China, says data and analytics company GlobalData. 11 August 2023
Biotechnology
Anglo-Swedish pharma major AstraZeneca’s research into mRNA vaccines is to be aided by the use of Chinese biotech firm CanSino Biologics' manufacturing platform. 10 August 2023
article
Japanese drug major Astellas Pharma has announced a strategic investment to support the advancement of Poseida Therapeutics’ commitment to redefining cancer cell therapy. The news pushed Poseida’s shares up as much as 24% to $2.69. 9 August 2023
Biotechnology
South Korean vaccine developer SK bioscience’s shares were up 4.6% at 84,500 won, after it announced its decision to make an equity investment of around $85 million in US biotech Novavax. 9 August 2023
Biotechnology
Sino-American biotech Terns Pharmaceuticals yesterday revealed positive top-line results from the Phase IIa DUET clinical trial of TERN-501, both alone and in combination with TERN-101, for the treatment of non-alcoholic steatohepatitis (NASH). 9 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) approved Japanese drug major Astellas Pharma’s Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) late Friday, 7 August 2023
Biotechnology
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil), developed by Taiho Oncology Inc and Taiho Pharmaceutical, subsidiaries of Japanese drugmaker Otsuka Holdings, with the decision coming ahead of the August 13 expected date. 3 August 2023
Biosimilars
South Korea’s Samsung Bioepis and USA-based Organon have announced the interchangeable result of its Humira (adalimumab) biosimilar, SB5, based on a recently conducted Phase IV study. 3 August 2023
Biotechnology
Japanese companies have been slow to progress COVID-19 vaccines, but today Daiichi Sankyo announced that it has received approval for the manufacturing and marketing of Daichirona for Intramuscular Injection (DS-5670). 2 August 2023
Pharmaceutical
German family-owned drugmaker Grünenthal and Japan’s Kyowa Kiron today announced the successful completion of a deal to enter into a joint venture collaboration for Kyowa Kirin International's established medicines portfolio. 2 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze